Vocational Studies. The Company shall open and maintain a “Keren Hishtalmut” Fund for the benefit of the Employee (the “Fund”). The Company shall contribute to such Fund an amount equal to 7-1/2% of the Salary and the Employee shall contribute to the Fund an amount equal to 2-1/2% of the Salary. The Employee hereby instructs the Company to transfer to the Fund Employee’s contribution from the Salary. Upon termination of this Agreement by either Party, other than termination by the Company for Cause, the Company shall assign and transfer to the Employee the ownership in the Fund.
Appears in 2 contracts
Samples: Employment Agreement (Protalix BioTherapeutics, Inc.), Employment Agreement (Orthodontix Inc)
Vocational Studies. The Company shall open and maintain a “Keren Hishtalmut” Fund for the benefit of the Employee (the “Fund”). The Company shall contribute to such Fund an amount equal to 7-1/27.5% of the Salary and the Employee shall contribute to the Fund an amount equal to 2-1/22.5% of the Salary. The Employee hereby instructs the Company to transfer to the Fund Employee’s contribution from the Salary. Upon termination of this Agreement by either Party, other than termination by the Company for Cause, the Company shall assign and transfer to the Employee the ownership in the Fund.
Appears in 1 contract
Samples: Employment Agreement (Protalix BioTherapeutics, Inc.)
Vocational Studies. The Company shall open and maintain a “"Keren Hishtalmut” " Fund for the benefit of the Employee (the “"Fund”"). The Company shall contribute to such Fund an amount equal to 7-1/2% of the Salary and the Employee shall contribute to the Fund an amount equal to 2-1/2% of the Salary. The Employee hereby instructs the Company to transfer to the Fund Employee’s 's contribution from the Salary. Upon termination of this Agreement by either Party, other than termination by the Company for Cause, the Company shall assign and transfer to the Employee the ownership in the Fund.
Appears in 1 contract
Samples: Employment Agreement (Protalix BioTherapeutics, Inc.)